Patent Litigation

Published: 18 December 2012

  • PEOPLE

    Thierry Calame
    Managing Partner, Co-Head of Intellectual Property
    M. Sterpi

  • Expertise

    Intellectual Property

  • Details

    Number of pages
    540 pages
    Publisher
    The European Lawyer Ltd.
    ISBN number
    978-1-908239-12-9

Following the success of the first edition of Patent Litigation, published in 2006 and widely well received by both practitioners and clients, this second edition aims to cover even more topics of importance to those involved in patent disputes.

To keep up with this continuously evolving area of law, more questions have been included addressing strategies for patent enforcement and defence, the role of expert evidence and the timescale for proceedings. A number of influential jurisdictions have also been added to this edition, making the coverage even more comprehensive and providing an indispensible guide to those involved in managing all aspects of patent litigation.

Related publications

SEE ALL

Insights

Insights – 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

Insights – 03.11.2025

Draft bill on communication platforms and search engines in Switzerland

Draft bill on communication platforms and search engines in Switzerland

SEE ALL
Lenz & Staehelin {PAGENO}/{nbpg}
{PAGENO}/{nbpg}